The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma.
Jun Guo
No relevant relationships to disclose
Chuan Liang Cui
No relevant relationships to disclose
Kangsheng GU
No relevant relationships to disclose
Min Tao
No relevant relationships to disclose
Song Xin
No relevant relationships to disclose
Tongyu Lin
No relevant relationships to disclose
Xiu Bao Ren
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose